Parkinson's Disease

Parkinson's disease is characterized by tremor, muscle stiffness, and problems with movement. Many factors, including genetics, can influence a person's chances of developing Parkinson's disease. This test includes two genetic variants associated with increased risk of developing the condition.

Jamie, you **do not have one** of the two genetic variants we tested.

Your result could not be determined for the other variant.

0 of 1 variants
detected in the GBA gene

1 variant not determined
in the LRRK2 gene

The test may not be able to determine a result for every variant tested. This can be caused by random test error or other factors that interfere with the test.

How To Use This Test

This test does not diagnose Parkinson's disease or any other health conditions.

Please talk to a healthcare professional if this condition runs in your family, you think you might have this condition, or you have any concerns about your results.

Review the Genetic Health Risk tutorial
See Scientific Details
See Frequently Asked Questions

Intended Uses

- Tests for the **G2019S** variant in the LRRK2 gene and the **N370S** variant in the GBA gene associated with an increased risk of developing Parkinson's disease.

Limitations

- Does **not** test for all possible variants or genes associated with Parkinson's disease.
- Does **not** test for any variants or genes linked to early-onset or young-onset Parkinson's disease.

Important Ethnicities

- The variants included in this test are most common and best studied in people of **European**, **Ashkenazi Jewish**, and **North African Berber** descent.

You **do not have one** of the two variants we tested associated with Parkinson's disease.

But your result could not be determined for the other variant.



Your result could not be determined for the G2019S variant in the LRRK2 gene.

This variant is most commonly found in people of **European**, **Ashkenazi Jewish**, and **North African Berber** descent. You do not have the N370S variant in the GBA gene.

See Scientific Details

There is still a chance of developing Parkinson's disease.

About 1 in 100 people develops Parkinson's disease during their lifetime, typically after the age of 55. Most cases of Parkinson's disease do not have a genetic cause. Keep in mind that other factors also influence your risk.

See Scientific Details



Environment and other factors can also influence the chances of developing Parkinson's disease.

Consult with a healthcare professional before making any major lifestyle changes.

Age

The risk of developing Parkinson's disease increases as a person ages. This condition is most often diagnosed in people over the age of 55.

See Scientific Details for more information

Age

Sex

Family history

Exposure to certain chemicals

About Parkinson's Disease

When it develops

Parkinson's disease typically develops in adulthood, after 55 years of age.

Typical signs and symptoms

- Tremor
- Muscle stiffness
- Slow movements
- Problems with balance
- Memory loss in some cases

How common is the condition?

Parkinson's disease affects people of all ethnicities. About 1 in 100 people develops Parkinson's disease during their lifetime.

How it's treated

There is currently no known prevention or cure for Parkinson's disease. Certain medications may be used to delay or ease symptoms. Speech, physical, and occupational therapies may also help with symptom management.

Read more at: Mayo Clinic National Institute of Neurological Disorders and Stroke GeneReviews The Michael J. Fox Foundation for Parkinson's Research

Learn more about Parkinson's disease.

See our Frequently Asked Questions for more information.

FAQs

If you have a family history of this condition or think you have symptoms, consult with a healthcare professional.

Print report

Receive up to $20 when you refer family and friends to 23andMe. Get started today.

Parkinson's Disease

Scientific Details

Parkinson's disease is characterized by tremor, muscle stiffness, and problems with movement. Many factors, including genetics, can influence a person's chances of developing Parkinson's disease. This test includes two genetic variants associated with increased risk of developing the condition.

Parkinson's disease is associated with variants in many genes.

This report includes one variant in the LRRK2 gene and one variant in the GBA gene. This test does not cover variants in other genes associated with Parkinson's disease.

LRRK2 GBA

The LRRK2 gene contains instructions for making an enzyme called leucine-rich repeat kinase 2, also called dardarin. This enzyme interacts with other proteins to turn them on and off. Certain variants in the LRRK2 gene cause this enzyme to be too active, which prevents it from properly controlling other proteins.

Read more at Genetics Home Reference



You do not have one of the two genetic variants we tested. Your result for the other tested variant could not be determined.

Variants Detected | View All Tested Markers

Marker Tested	Your Genotype*	Additional Information
G2019S Gene: LRRK2 Marker: rs34637584	**Not determined**	Biological explanation Typical vs. variant DNA sequence(s) Percent of 23andMe customers with variant References [4, 8, 9, 11, 12, 13, 19, 20, 21, 22, 23, 31] | ClinVar
N370S Gene: GBA Marker: i4000415	**T** Typical copy from one of your parents **T** Typical copy from your other parent	Biological explanation Typical vs. variant DNA sequence(s) Percent of 23andMe customers with variant References [1, 2, 18, 25, 28, 29, 34] | ClinVar

*This test cannot distinguish which copy you received from which parent. This test also cannot determine whether multiple variants, if detected, were inherited from only one parent or from both parents. This may impact how these variants are passed down.

23andMe always reports genotypes based on the 'positive' strand of the human genome reference sequence (build 37). Other sources sometimes report genotypes using the opposite strand.

Test Interpretation

This report provides risk estimates for people of European, Ashkenazi Jewish, and North African Berber descent. Estimates for other ethnicities are not currently available.

Health Risk Estimates

Risk estimates are based on clinical studies that identify an association between a genotype and a health condition.

Risk estimates are not available for people who have two copies of the G2019S variant or a combination of the two tested variants. An interpretation of "increased risk" is provided to people with these results because it is likely that their risk is at least as high as for people with one copy of the G2019S variant alone.

Consider talking to a healthcare professional if you have any concerns about your results.

References [1, 4, 7, 13, 14, 18, 23, 27, 31]

Lifetime risk | Likelihood ratios

The lifetime risk estimates shown below represent the proportion of people expected to develop Parkinson's disease by age 80. These values are based on studies conducted in people of European, Ashkenazi Jewish, and North African Berber descent. In the general population, about 1 in 100 people (1%) develops Parkinson's disease during their lifetime, typically after the age of 55.

Genotype	Ashkenazi Jewish	European	North African Berber
One copy of G2019S variant	26%	24%	91%
One copy of N370S variant	5.9%	Slightly increased risk (exact estimate not available)	Not available
Two copies of N370S variant	9.1%	Not available	Not available

Other Factors

Other factors besides the variants included in this test can influence your chances of developing Parkinson's disease.

This is not a complete list of other factors.

People with multiple risk factors may have a higher risk of developing Parkinson's disease.

Consult with a healthcare professional before making any major lifestyle changes.

Other Factors	References
Age The risk of developing Parkinson's disease increases as a person ages. This condition is most often diagnosed in people over the age of 55.	[6]
Sex Men have a higher chance of developing Parkinson's disease than women. The exact reason for this difference between the sexes is unknown. Researchers have proposed that it may be due to higher rates of occupation-related head injury and chemical exposure in men, or that women may be protected by higher estrogen levels.	[6, 24, 32]
Family history First-degree relatives of an individual with Parkinson's disease have a higher chance of developing Parkinson's disease themselves. The risk in individuals with a family history of Parkinson's disease is estimated to be about 3-7%, compared to 1-2% in the general population.	[6, 16, 26]
Exposure to certain chemicals Exposure to certain chemicals increases the risk of developing Parkinson's disease. These include chemicals used in agriculture, such as pesticides.	[6, 26]
Physical activity People who engage in physical activity have a lower risk of developing Parkinson's disease compared to people who rarely or never do. This effect is strongest in people who report engaging in moderate or vigorous physical activity. Some studies suggest that the effect is stronger for men than it is for women.	[3, 30, 33]
Head injury Some studies suggest an association between certain types of head injury and increased risk of developing Parkinson's disease later in life. Head injury that results in prolonged loss of consciousness appears to have the strongest association. Some researchers think that this might be due to inflammation in the brain after the injury.	[5, 15]
Other genes There are other genes and variants that have been linked to Parkinson's disease. However, most of these variants are either rare or have only a small effect on risk.	[6]

Test Details

Indications for Use

The 23andMe PGS Genetic Health Risk Report for Parkinson's Disease is indicated for reporting of the G2019S variant in the LRRK2 gene and the N370S variant in the GBA gene. This report describes if a person's genetic result is associated with an increased risk of developing Parkinson's disease, but it does not describe a person's overall risk of developing Parkinson's disease. This report is most relevant for people of European, Ashkenazi Jewish, and North African Berber descent.

Special Considerations

- Genetic testing for Parkinson's disease is not currently recommended by any healthcare professional organizations.

Test Performance Summary

Clinical Performance [6, 10, 17, 27, 29]

The genes and variants included in this report only represent a subset of all those that have been associated with Parkinson's disease. The two variants tested are associated with an increased risk of developing Parkinson's disease. However, many people who have one or both of these variants do not develop the condition. In addition, most cases of Parkinson's disease do not have a genetic cause.

- 1-2% of people with Parkinson's disease have the G2019S variant in the LRRK2 gene. Among people with familial Parkinson's disease, 5-7% have this variant.
- 8-14% of people with Parkinson's disease have a variant in the GBA gene. The N370S variant accounts for roughly half of those cases.

Analytical Performance

Accuracy was determined by comparing results from this test with results from sequencing for 187 samples. 187 out of 187 genotype results were correct. While unlikely, this test may provide false positive or false negative results.

Warnings and Limitations

- This test does not cover all variants that could cause this condition.*
- This test does not diagnose any health conditions.
- Share results with your healthcare professional for any medical purposes.
- If you are concerned about your results, consult with a healthcare professional.

See the Package Insert for more details on use and performance of this test.

* Variants not included in this test may be very rare, may not be available on our genotyping platform, or may not pass our testing standards.

References

1. Alcalay RN et al. (2014). "Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes." JAMA Neurol. 71(6):752-7.
2. Asselta R et al. (2014). "Glucocerebrosidase mutations in primary parkinsonism." Parkinsonism Relat Disord. 20(11):1215-20.
3. Chen H et al. (2005). "Physical activity and the risk of Parkinson disease." Neurology. 64(4):664-9.
4. Clark LN et al. (2006). "Frequency of LRRK2 mutations in early- and late-onset Parkinson disease." Neurology. 67(10):1786-91.
5. Crane PK et al. (2016). "Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings." JAMA Neurol. 73(9):1062-9.
6. Farlow J et al. (1993). "Parkinson Disease Overview" In: Pagon RA et al., editors. GeneReviews. [updated 2014 Feb 27]
7. Gan-Or Z et al. (2015). "Differential effects of severe vs mild GBA mutations on Parkinson disease." Neurology. 84(9):880-7.
8. Garcia-Miralles M et al. (2015). "No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts." PLoS One. 10(4):e0118947.
9. Goldwurm S et al. (2011). "Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease." Mov Disord. 26(11):2144-5.
10. Healy DG et al. (2008). "Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study." Lancet Neurol. 7(7):583-90.
11. Hentati F et al. (2014). "LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance." Neurology. 83(6):568-9.
12. Hulihan MM et al. (2008). "LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study." Lancet Neurol. 7(7):591-4.
13. Ishihara L et al. (2006). "Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations." Arch Neurol. 63(9):1250-4.
14. Ishihara L et al. (2007). "Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families." Mov Disord. 22(1):55-61.
15. Jafari S et al. (2013). "Head injury and risk of Parkinson disease: a systematic review and meta-analysis." Mov Disord. 28(9):1222-9.
16. Kenborg L et al. (2015). "Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study." Am J Epidemiol. 181(10):808-16.
17. Klein C et al. (2012). "Genetics of Parkinson's disease." Cold Spring Harb Perspect Med. 2(1):a008888.
18. Lesage S et al. (2011). "Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease." Hum Mol Genet. 20(1):202-10.
19. Lin CH et al. (2010). "LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß." J Neurosci. 30(39):13138-49.
20. Luzon-Toro B et al. (2007). "Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation." Hum Mol Genet. 16(17):2031-9.
21. MacLeod D et al. (2006). "The familial Parkinsonism gene LRRK2 regulates neurite process morphology." Neuron. 52(4):587-93.
22. Manzoni C et al. (2013). "Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation." Biochem Biophys Res Commun. 441(4):862-6.
23. Marder K et al. (2015). "Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium." Neurology. 85(1):89-95.
24. Moisan F et al. (2015). "Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis." J Neurol Neurosurg Psychiatry. 2015 Dec 23.
25. Montfort M et al. (2004). "Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and "modifier" polymorphisms." Hum Mutat. 23(6):567-75.
26. Noyce AJ et al. (2012). "Meta-analysis of early nonmotor features and risk factors for Parkinson disease." Ann Neurol. 72(6):893-901.
27. Orr-Urtreger A et al. (2007). "The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?" Neurology. 69(16):1595-602.
28. Rana HQ et al. (2013). "Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling." Genet Med. 15(2):146-9.
29. Sidransky E et al. (2009). "Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease." N Engl J Med. 361(17):1651-61.
30. Thacker EL et al. (2008). "Recreational physical activity and risk of Parkinson's disease." Mov Disord. 23(1):69-74.
31. Trinh J et al. (2014). "Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism." Neurobiol Aging. 35(5):1125-31.
32. Wooten GF et al. (2004). "Are men at greater risk for Parkinson's disease than women?" J Neurol Neurosurg Psychiatry. 75(4):637-9.
33. Xu Q et al. (2010). "Physical activity and future risk of Parkinson disease." Neurology. 75(4):341-8.
34. Yap TL et al. (2011). "Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases." J Biol Chem. 286(32):28080-8.

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.

Date	Change
April 17, 2017	Parkinson's Disease report created.

Receive up to $20 when you refer family and friends to 23andMe. Get started today.

Parkinson's Disease

Frequently Asked Questions

Parkinson's disease is characterized by tremor, muscle stiffness, and problems with movement. Many factors, including genetics, can influence a person's chances of developing Parkinson's disease. This test includes two genetic variants associated with increased risk of developing the condition.

Parkinson's Disease

What does this test do?

This test looks for two specific genetic variants associated with Parkinson's disease, one in the LRRK2 gene called G2019S, and one in the GBA gene called N370S.

People with the genetic variants included in this test are more likely to develop Parkinson's disease. However, not everyone with these genetic variants will develop the condition.

This test does not include all possible genetic variants that may increase your risk of developing Parkinson's disease.

This test does not include any genetic variants or genes linked to early-onset or young-onset Parkinson's disease.

Is this answer helpful? Yes No

What does this test not do?

This test does not diagnose Parkinson's disease. Only a healthcare professional can do that.

This test does not tell you if you have Parkinson's disease or if you will definitely develop the condition in the future.

This test does not take into account other risk factors for Parkinson's disease, such as personal and family health history. Thus, this test cannot provide a complete assessment of your risk of developing the condition.

This test does not include all possible genetic variants that may increase your risk of developing Parkinson's disease.

This test does not include any genetic variants or genes linked to early-onset or young-onset Parkinson's disease.

Is this answer helpful? Yes No

The report says the variants included in this test are most common and best studied in people of European, Ashkenazi Jewish, and North African Berber descent. What if I'm not of European, Ashkenazi Jewish, or North African Berber descent?

The tested variants are expected to be less common in people who are not of European, Ashkenazi Jewish, and North African Berber descent.

The effect of these variants on a person's risk of developing Parkinson's disease is well understood in people of European, Ashkenazi Jewish, and North African Berber descent. If you have one or more of these genetic variants but are of a different ethnicity, you are still expected to have a higher risk of developing Parkinson's disease, but the exact risk numbers are not well understood. See Scientific Details for more information.

There are other genetic variants associated with an increased risk of developing Parkinson's disease in other ethnicities. These other variants are not included in this test. It is still possible for a person to have one of these genetic variants not covered by this test.

Is this answer helpful? Yes No

Where can I learn more about Parkinson's disease, support groups, and other resources?

You can learn more about Parkinson's disease from the following resources:

- American Parkinson Disease Association
- The Michael J. Fox Foundation for Parkinson's Research
- Parkinson's Disease Foundation
- Parkinson's Institute and Clinical Center

If you have questions about your results or how they might affect you or your family, a genetic counselor may be able to help. Learn more about genetic counseling.

Is this answer helpful? Yes No

My report says I do not have one of the tested genetic variants but my result for one variant could not be determined. What does this mean?

You do not have one of the two genetic variants we tested. But we could not tell if you have the other tested genetic variant. This can be caused by random test error or other factors that interfere with the test.

It is still possible to develop Parkinson's disease. About 1 in 100 people develops Parkinson's disease during their lifetime, typically after the age of 55. Most cases of Parkinson's disease do not have a genetic cause.

Other factors can also affect your risk of developing Parkinson's disease, even if you do not have any genetic variants. Learn more about other factors.

Is this answer helpful? Yes No

What does it mean if the result for a variant could not be determined?

This means we could not tell if you do or do not have the tested genetic variant. This can be caused by random test error or other factors that interfere with the test.

Is this answer helpful? Yes No

My report says I do not have one of the tested genetic variants but my result for one variant could not be determined. What are some things I could do?

This genetic result is not associated with an increased risk of developing Parkinson's disease. However, it is still possible to have the genetic variant that could not be determined or another genetic variant not tested. Non-genetic factors can also affect your risk. Learn more about other factors.

Consider talking to a healthcare professional if:

- Parkinson's disease runs in your family.
- You think you might have Parkinson's disease.
- You have questions about other risk factors you may have.

Is this answer helpful? Yes No

Have more questions? Check out our Customer Care Help Center.

Receive up to $20 when you refer family and friends to 23andMe. Get started today.